Janssen Pharmaceutica Nv

Ortho-mcneil Pharmaceutical Corp.

Ortho-mcneil Pharmaceuticlas, Inc.

Richard Apodaca

Wei Xiao

Chandravadan R Shah

Nicholas I Carruthers

Curt A Dvorak

J Guy Breitenbucher

Jill A Jablonowski

Mark Seierstad

Neelakandha S Mani

Xiaohu Deng

Kanaka Pattabiraman

John M Keith

Chennagiri R Pandit

Ronald L Wolin

Timothy W Lovenberg

Dale A Rudolph

Ann J Barbier

Leslie A Gomez

Devin M Swanson

Natalie Anne Hawryluk

Kiev S Ly

Jeffrey E Merit

Alison L Chambers

Joan M Pierce

Certain piperazinyl and piperidinyl urea compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).

Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase

Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.

Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase

Certain hexahydro-pyrrolo-isoquinoline compounds are histamine Hreceptor and serotonin transporter modulators useful in the treatment of histamine Hreceptor- and serotonin-mediated diseases.

Hexahydro-pyrrolo-isoquinoline compounds

Certain N-heteroarylpiperazinyl urea compounds of Formula (I), as defined in the specification, are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis). 

N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase

Substituted phenylalkynes of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.

Phenylalkynes

Substituted aryloxyalkylamines of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.

Non-imidazole aryloxyalkylamines

Substituted piperazinyl and diazepanyl benzamides and benzthioamides of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.

Piperazinyl and diazapanyl benzamides and benzthioamides

Substituted phenylalkynes of formula (I) compositions containing them and their methods of use to treat histamine related disorders are described, wherein R, R, R, R, Rand n are as defined.

Substituted phenylpiperidines and phenylpyrrolidines of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.

Phenylpiperidines and phenylpyrrolidines

Substituted non-imidazole aryloxypiperidine compounds, compositions containing them, and methods of making and using them to treat or prevent histamine-mediated conditions.

Growing community of inventors

San Diego, CA, United States of America

Richard Apodaca